NEW YORK – Precision medicine, sequencing, and bioinformatics company Tempus said Tuesday that it has acquired oncology-focused contract research organization Highline Sciences. Terms were not disclosed.
Chicago-based Tempus said that the acquisition of the CRO will help it expand existing business lines and build new ones by vertically integrating clinical trial services. Tempus historically has relied on partnerships with external CROs.
San Francisco-based Highline manages and conducts early- and late-stage clinical trials.
"We are committed to improving the current clinical trial model and are always seeking new ways to advance how studies are designed and executed so that we can bring clinical trials to the patients that need them most," Tempus Founder and CEO Eric Lefkofsky said in a statement.
"Joining forces with Tempus creates a unique offering for customers and new, innovative approaches to improving clinical research services and accelerating the development of promising therapies," added Highline Sciences Founder and CEO Collin Williams.